KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Sales and Divestitures (2018 - 2020)

Historic Gains from Sales and Divestitures for Esperion Therapeutics (ESPR) over the last 3 years, with Q2 2020 value amounting to $53587.0.

  • Esperion Therapeutics' Gains from Sales and Divestitures rose 42795.07% to $53587.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $53587.0, marking a year-over-year increase of 42795.07%. This contributed to the annual value of $17710.0 for FY2019, which is 41527.49% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Gains from Sales and Divestitures of $53587.0 as of Q2 2020, which was up 42795.07% from $10089.0 recorded in Q1 2020.
  • Esperion Therapeutics' 5-year Gains from Sales and Divestitures high stood at $53587.0 for Q2 2020, and its period low was $1562.0 during Q1 2018.
  • Over the past 3 years, Esperion Therapeutics' median Gains from Sales and Divestitures value was $6763.0 (recorded in 2018), while the average stood at $11850.9.
  • As far as peak fluctuations go, Esperion Therapeutics' Gains from Sales and Divestitures soared by 10006.4% in 2019, and later surged by 42795.07% in 2020.
  • Over the past 3 years, Esperion Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $3437.0 in 2018, then surged by 415.27% to $17710.0 in 2019, then surged by 202.58% to $53587.0 in 2020.
  • Its last three reported values are $53587.0 in Q2 2020, $10089.0 for Q1 2020, and $17710.0 during Q4 2019.